B

BioCryst Pharmaceuticals

Develops oral drugs for rare diseases

Executive Director of Biostatistics

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
PhD
Boston, MA, USA+1 moreMore locations: North Carolina, USA
Remote
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A Ph.D. in Biostatistics or a related field, with at least 12 years of pharmaceutical industry experience and 10 or more years in clinical trial design, analysis, and interpretation, or an equivalent combination of education and experience.
  • Deep understanding of SAS programming sufficient to oversee statistical programming and program as needed.
  • Strong leadership and interpersonal skills.
  • NDA filing experience, including serving as a key contributor to one or more successful product approvals.
  • Expertise in biostatistics, programming, and clinical data management disciplines, practices, and procedures, including developing and being accountable for relevant quality management systems.
  • Knowledge of the clinical development process and relevant regulatory guidelines and requirements.
  • Experience with Data Monitoring Committees and/or study steering committees.
  • A hands-on approach, including conducting analyses when necessary.
  • Experience with European and Japanese regulatory agencies.
  • Formal expertise and experience in Bayesian and frequentist statistics.
  • Flexible scheduling and ability to travel internationally.
  • Responsiveness and ability to prioritize effectively.
Responsibilities
  • Lead conduct and analysis of BioCryst-sponsored Phase I to Phase IV clinical studies and selected non-clinical studies.
  • Provide biostatistics support for sponsored clinical studies, selected non-clinical studies, and Medical Affairs.
  • Ensure the relevance and adequacy of statistical methods used in clinical development activities and selected non-clinical studies.
  • Ensure conformance to relevant regulatory guidelines and Good Clinical Practice.
  • Ensure Biostatistics contributes to clinical development strategies, including optimal development programs and study design.
  • Oversee CRO and contract staff performing outsourced operational activities; review and approve contracts, work orders, and invoices within delegated authority.
  • Act as project statistician for an individual project.
  • Participate in FDA and other regulatory agency meetings as the Company’s spokesperson for biostatistical topics.
  • Apply innovative regulatory biostatistics approaches, including maximizing learning from Phase 2 experiments and designing and analyzing Phase 3b/4 studies to maximize product life cycle.
  • Participate in organization-wide process definition, creation, and implementation, with a focus on efficiency and productivity.
  • Define, monitor, and evaluate relevant performance metrics.
  • Author and review relevant sections of critical product-development documents, including clinical study protocols, statistical analysis plans, data management plans, regulatory briefing documents, NDAs, MAAs, responses to regulatory questions, scientific abstracts, and manuscripts.
  • Ensure accuracy of data in public corporate communications of clinical trial results, including press releases, slide presentations, SEC filings, scientific meeting abstracts, and published manuscripts; monitor the quality audit process for these communications.
  • Communicate technical concepts to technical and regulatory audiences and to broader audiences in nontechnical language without loss of rigor.
  • Perform other duties as assigned.
Desired Qualifications
  • Management experience is preferred.
  • Experience supporting Medical Affairs and post-marketing studies is an added benefit.

About the company

B

BioCryst Pharmaceuticals

View

BioCryst Pharmaceuticals develops oral small-molecule drugs aimed at treating rare diseases, with a focus on hereditary angioedema (HAE). The company uses traditional cell biology and medicinal chemistry to design synthetic compounds that target specific protein pathways involved in disease. Its products work as oral therapies that modulate disease-related proteins to reduce symptoms and improve daily functioning, progressing from discovery through clinical trials toward commercialization. BioCryst differentiates itself by concentrating on rare diseases and pursuing oral, non-biologic treatments, leveraging a combined science approach and a patient-focused strategy to bring therapies to market. Its goal is to deliver meaningful, clinically validated treatments that enable patients to engage more fully in everyday activities and improve their quality of life, supported by its drug pipeline and potential licensing opportunities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1986

Get referred to BioCryst Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Japan approved pediatric Orladeyo on August 26, 2026, expanding revenue outside America.
  • Q2 2026 revenue hit $218.3 million, and management raised 2026 guidance to $715 million.
  • CareMed became a national Orladeyo partner on September 8, 2026, widening U.S. access.

What critics are saying

  • Pharvaris plans HAE approval in 2027, threatening Orladeyo pricing and persistence.
  • BioCryst closed Hoover in October 2026, laying off 47 and shrinking discovery capacity.
  • Orladeyo concentration remains existential; one HAE franchise funds BioCryst until navenibart proves itself.

What makes BioCryst Pharmaceuticals unique

  • Orladeyo is the only oral HAE prophylaxis approved for children aged two.
  • BioCryst now commercializes globally through specialty partners like OrphanPacific and CareMed.
  • Management quit internal discovery in 2026, focusing capital on external rare-disease asset acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

6 month growth

4%

1 year growth

5%

2 year growth

5%
Associated Press
Oct 21st, 2026
FDA approves BioCryst's Orladeyo oral pellets for adults and adolescents with HAE

BioCryst Pharmaceuticals said the US Food and Drug Administration (FDA) has approved an oral pellet formulation of its once-daily drug ORLADEYO (berotralstat) for adults and adolescents aged 12 and older with hereditary angioedema (HAE). The 150mg pellets prevent HAE attacks. The pellets suit patients who have difficulty swallowing or prefer not to take a capsule. They can be swallowed with water or milk, or sprinkled over a spoonful of soft, non-acidic food. The approval was based on manufacturing data and evidence of the pellets' safety and tolerability compared with capsules. The FDA approved the pellets for children aged 2 to under 12 in December 2025. In two clinical studies, ORLADEYO capsules cut the mean attack rate by 91% at 96 weeks.

Asianet News
Sep 9th, 2026
BCRX stock posts worst day in over 6 months after PHVS trial win in rare swelling disease.

BCRX stock posts worst day in over 6 months after PHVS trial win in rare swelling disease. Published: Sep 09 2026, 05:00 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. * BioCryst's Orladeyo is approved to prevent HAE attacks. * Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million in revenue from the drug this year. * BioCryst CEO Charlie Gayer said last month that the company wants to buy rare-disease medicines after Orladeyo's success. Shares of BioCryst Pharmaceuticals (BCRX) fell sharply on Tuesday after a competitor reported strong late-stage results in hereditary angioedema, the rare swelling disorder that underpins BioCryst's main product. BCRX fell 9% on Tuesday and clocked its worst day since late February. A rival pill raises the bar. The pressure came from Pharvaris (PHVS), which said its once-daily experimental pill cut monthly swelling attacks by 83% compared with a dummy treatment in a late-stage study. In the two most common forms of the disease, attacks fell by 87%. The medicine was generally well tolerated, and Pharvaris plans to seek approval in the first half of 2027. PHVS shares jumped 7% in regular trading and another 3% after-hours. That market is the same one served by BioCryst's Orladeyo, an approved once-daily capsule used to prevent attacks. Investors marked down Orladeyo on the risk of a stronger oral rival after 2027. Orladeyo market. Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million from the drug this year. A pellet version for young children has begun shipping after an earlier manufacturing delay. The drug has generated more than $2 billion in revenue since U.S. approval in 2020. BioCryst is also developing a second hereditary angioedema medicine, navenibart, with late-stage data still expected in 2027. BioCryst CEO Charlie Gayer said last month that the company wants to buy rare-disease medicines after Orladeyo's success. Gayer has said the next products should come from outside deals, not its own lab. Larger drugmakers have been chasing bigger assets. BioCryst is positioning itself as a buyer in the rare-disease gap they leave behind. How did BCRX retail traders react? On Stocktwits, retail sentiment around BCRX rose from 'bearish' to 'neutral' over the past 24 hours, while message volume jumped from 'low' to 'high' levels. A Stocktwits user dismissed Tuesday's selloff, noting that the company already has a real commercial product. "I'm really not worried... it will go up sooner than later... market trying to get rid of the weak hands," they said. View this Stocktwits post Another user opined that no one will switch out of Orladeyo even if Pharvaris's drug gets approved. It also noted that PHVS is valued higher than BCRX despite having no approved products. View this Stocktwits post BCRX stock has gained 16% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com. Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

The Manila Times
Sep 8th, 2026
CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio.

CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio. By GlobeNewswire September 9, 2026 NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) - CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo(R)(berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.1 "The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty platform in delivering high-touch, patient-centric care across rare, cancer, and orphan disease communities, and further positions us as a trusted partner for patients, providers, and manufacturers," said Benito Fernandez, Chief Commercial Officer. About CareMed Specialty Pharmacy: CareMed is an independent Specialty Pharmacy affiliate of Onco360 and leading clinical support services company. CareMed is committed to bringing together the stakeholders involved in the rare and complex disease treatment process and serve the specialized needs of patients, providers, hospitals, manufacturers, health plans, and payers. CareMed is headquartered in New Hyde Park, New York, and is a specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. It is accredited through URAC, URAC Rare Disease, ACHC, and NAPB. For more information about CareMed, please visit CareMed.com. Media Contact: Benito Fernandez, Chief Commercial Officer References: 1Orladeyo(R)(berotralstat) [Package Insert]. Durham, NC. BioCryst Pharmaceuticals, Inc. 2025.

BrightSpring Health Services
Sep 8th, 2026
CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio.

CareMed has been selected as a national pharmacy partner by BioCryst and adds Orladeyo(R)(berotralstat) to growing Rare Disease portfolio. September 8, 2026 CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo(R)(berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.[1] "The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty platform in delivering high-touch, patient-centric care across rare, cancer, and orphan disease communities, and further positions us as a trusted partner for patients, providers, and manufacturers," said Benito Fernandez, Chief Commercial Officer. About CareMed Specialty Pharmacy: CareMed is an independent Specialty Pharmacy affiliate of Onco360 and leading clinical support services company. CareMed is committed to bringing together the stakeholders involved in the rare and complex disease treatment process and serve the specialized needs of patients, providers, hospitals, manufacturers, health plans, and payers. CareMed is headquartered in New Hyde Park, New York, and is a specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. It is accredited through URAC, URAC Rare Disease, ACHC, and NAPB. For more information about CareMed, please visit CareMed.com. Media Contact Benito Fernandez, Chief Commercial Officer References: [1] Orladeyo(R)(berotralstat) [Package Insert]. Durham, NC. BioCryst Pharmaceuticals, Inc. 2025.

CNBC
Aug 28th, 2026
BioCryst eyes rare disease M&A as Orladeyo hits $645M in 2026 sales

BioCryst Pharmaceuticals is leveraging profits from its hereditary angioedema drug Orladeyo to acquire rare disease treatments. The company expects up to $645 million in 2026 sales from Orladeyo, which has generated over $2 billion since its 2020 FDA approval. CEO Charlie Gayer said BioCryst became profitable last year and aims to maintain profitability whilst expanding beyond being a single-product company. The firm is now seeking external acquisitions rather than internal development, targeting assets with peak sales around $300 million. This shift reflects a broader trend where small and midsize biotech companies are stepping into rare disease drug development as large pharmaceutical firms increasingly focus on multibillion-dollar assets. BioCryst's shares have risen approximately 25% since the start of the year.